FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904305514> ?p ?o ?g. }

• W2904305514 endingPage "23" @default.
• W2904305514 startingPage "16" @default.
• W2904305514 abstract "Background Patients with warfarin have a potential risk of warfarin-related nephropathy, which could result in the discontinuation of anticoagulation therapy. The question of whether non-vitamin K antagonist oral anticoagulants (NOACs) use is associated with increased risk of renal impairment in atrial fibrillation (AF) patients remains unanswered. Methods Studies were systematically searched through Medline, Embase, Cochrane Library databases, and ClinicalTrials.gov Website. Randomized controlled trials (RCTs) reporting renal impairment events and observational nationwide database studies presenting adjusted hazard ratio (HR) in AF patients with NOACs were identified. The Primacy outcome was renal impairment, defined as a composite of any renal disorder. The secondary outcomes were narrow definition of renal failure (including renal failure, acute renal failure, chronic renal failure, acute prerenal failure and postrenal failure) and individual renal impairment reported in involved studies. HR and 95% confidence intervals (95%CI) were calculated using fixed- or random-effects models according to the extent of heterogeneity. Subgroup analyses were conducted according to individual NOACs, study types and different controls. Results Totally, 189,483 patients from 11 RCTs and 3 observational database studies were included in the analysis (119,188 patients with NOACs and 70,295 patients with vitamin K Antagonists or acetylsalicylic acid). Overall results indicated a significantly lower risk of renal impairment in AF patients with NOACs versus VKAs/acetylsalicylic acid (HR: 0.67, 95%CI: 0.62–0.73). Results of narrow definition of renal impairment were accordant with the primacy outcome (HR: 0.65, 95%CI: 0.60–0.71). Compared with VKAs or acetylsalicylic acid, dabigatran (HR: 0.64, 95%CI: 0.56–0.72), rivaroxaban (HR: 0.66, 95%CI: 0.55–0.77) and apixaban (HR: 0.73, 95%CI: 0.59–0.87) were all associated with a significantly lower risk of renal impairment, with the exception of edoxaban (HR: 0.79, 95%CI: 0.30–1.27). Conclusions Patients with NOACs might bring about a lower risk of renal impairment compared to VKA or acetylsalicylic acid. Further specialized designs of RCTs and real-world studies on evaluation of renal function are warranted to obtain a robust result on this issue." @default.
• W2904305514 created "2018-12-22" @default.
• W2904305514 creator A5001190304 @default.
• W2904305514 creator A5003374713 @default.
• W2904305514 creator A5011405813 @default.
• W2904305514 creator A5016880048 @default.
• W2904305514 creator A5045258292 @default.
• W2904305514 creator A5057548382 @default.
• W2904305514 creator A5062429074 @default.
• W2904305514 creator A5079781528 @default.
• W2904305514 date "2019-02-01" @default.
• W2904305514 modified "2023-10-16" @default.
• W2904305514 title "Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies" @default.
• W2904305514 cites W1482390718 @default.
• W2904305514 cites W1964435302 @default.
• W2904305514 cites W1982653307 @default.
• W2904305514 cites W1999468381 @default.
• W2904305514 cites W2008493502 @default.
• W2904305514 cites W2010152642 @default.
• W2904305514 cites W2013217031 @default.
• W2904305514 cites W2032295354 @default.
• W2904305514 cites W2038507245 @default.
• W2904305514 cites W2072179271 @default.
• W2904305514 cites W2094924708 @default.
• W2904305514 cites W2096246254 @default.
• W2904305514 cites W2107020336 @default.
• W2904305514 cites W2126930838 @default.
• W2904305514 cites W2149388786 @default.
• W2904305514 cites W2159357148 @default.
• W2904305514 cites W2162508946 @default.
• W2904305514 cites W2267081097 @default.
• W2904305514 cites W2320128544 @default.
• W2904305514 cites W2421809065 @default.
• W2904305514 cites W2518330835 @default.
• W2904305514 cites W2540776065 @default.
• W2904305514 cites W2556417520 @default.
• W2904305514 cites W2556994020 @default.
• W2904305514 cites W2583356829 @default.
• W2904305514 cites W2595627091 @default.
• W2904305514 cites W2738999115 @default.
• W2904305514 cites W2768325747 @default.
• W2904305514 cites W2792857103 @default.
• W2904305514 cites W2794675646 @default.
• W2904305514 cites W2795632834 @default.
• W2904305514 cites W2807204637 @default.
• W2904305514 cites W3023357416 @default.
• W2904305514 cites W594767912 @default.
• W2904305514 doi "https://doi.org/10.1016/j.thromres.2018.12.010" @default.
• W2904305514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30551039" @default.
• W2904305514 hasPublicationYear "2019" @default.
• W2904305514 type Work @default.
• W2904305514 sameAs 2904305514 @default.
• W2904305514 citedByCount "22" @default.
• W2904305514 countsByYear W29043055142020 @default.
• W2904305514 countsByYear W29043055142021 @default.
• W2904305514 countsByYear W29043055142022 @default.
• W2904305514 countsByYear W29043055142023 @default.
• W2904305514 crossrefType "journal-article" @default.
• W2904305514 hasAuthorship W2904305514A5001190304 @default.
• W2904305514 hasAuthorship W2904305514A5003374713 @default.
• W2904305514 hasAuthorship W2904305514A5011405813 @default.
• W2904305514 hasAuthorship W2904305514A5016880048 @default.
• W2904305514 hasAuthorship W2904305514A5045258292 @default.
• W2904305514 hasAuthorship W2904305514A5057548382 @default.
• W2904305514 hasAuthorship W2904305514A5062429074 @default.
• W2904305514 hasAuthorship W2904305514A5079781528 @default.
• W2904305514 hasConcept C126322002 @default.
• W2904305514 hasConcept C168563851 @default.
• W2904305514 hasConcept C187960798 @default.
• W2904305514 hasConcept C207103383 @default.
• W2904305514 hasConcept C23131810 @default.
• W2904305514 hasConcept C2776301958 @default.
• W2904305514 hasConcept C2776704044 @default.
• W2904305514 hasConcept C2778715236 @default.
• W2904305514 hasConcept C2779161974 @default.
• W2904305514 hasConcept C44249647 @default.
• W2904305514 hasConcept C71924100 @default.
• W2904305514 hasConcept C82789193 @default.
• W2904305514 hasConcept C95190672 @default.
• W2904305514 hasConceptScore W2904305514C126322002 @default.
• W2904305514 hasConceptScore W2904305514C168563851 @default.
• W2904305514 hasConceptScore W2904305514C187960798 @default.
• W2904305514 hasConceptScore W2904305514C207103383 @default.
• W2904305514 hasConceptScore W2904305514C23131810 @default.
• W2904305514 hasConceptScore W2904305514C2776301958 @default.
• W2904305514 hasConceptScore W2904305514C2776704044 @default.
• W2904305514 hasConceptScore W2904305514C2778715236 @default.
• W2904305514 hasConceptScore W2904305514C2779161974 @default.
• W2904305514 hasConceptScore W2904305514C44249647 @default.
• W2904305514 hasConceptScore W2904305514C71924100 @default.
• W2904305514 hasConceptScore W2904305514C82789193 @default.
• W2904305514 hasConceptScore W2904305514C95190672 @default.
• W2904305514 hasFunder F4320321001 @default.
• W2904305514 hasFunder F4320326187 @default.
• W2904305514 hasLocation W29043055141 @default.
• W2904305514 hasLocation W29043055142 @default.
• W2904305514 hasOpenAccess W2904305514 @default.
• W2904305514 hasPrimaryLocation W29043055141 @default.

• next